Dataset opportunity
Shinefusion — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Shinefusion, usable for Diagnostic AI and Computer Vision.
Score
45
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
Global Artificial Intelligence in Diagnostics Market was valued at USD 1.5 billion in 2024, with a projected CAGR of 21.5% (2025-2034) (source: Global Market Insights Inc.). [1]
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-06-19
Valar Atomic’s Ward 250 Becomes Second Reactor to Go Critical Under DOE Pilot Program
powermag.com ↗ - 📰press2026-06-18
In a First for Advanced Nuclear: Siemens Energy Turbine Package Advances for Oklo’s Aurora-INL
powermag.com ↗ - 📰press2026-06-18
Mining’s nuclear reality check: SMRs are still not on miners’ shopping lists
mining.com ↗ - 📰press2026-06-18
Centrus Energy, Oklo sign multi-year nuclear fuel deal
mining.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- 🧑💻Hiring a data role
Recruits for Controls and Software Engineers for fusion systems
source ↗
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
industrial
Volume
Moderate
Freshness
Real-time
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — restricted · PII/regulated
Buyer persona
Medical-AI & diagnostic-imaging companies
Shinefusion holds a substantial Medical Imaging Dataset, comprised of high-resolution images suitable for training Diagnostic AI models. The data originates from highly-regulated industrial and medical contexts, ensuring a unique and consistent quality standard. This collection includes diverse imaging evidence from medical records, making it a robust foundation for developing and validating advanced diagnostic algorithms.
The value of this data is underscored by the booming AI in Diagnostics market, which was valued at USD 1.5 billion in 2024 and is projected to grow at a CAGR of 21.5%. [1] While access is subject to negotiation due to the highly regulated nuclear and medical sectors and DOE oversight, this complexity ensures the data's rarity and high value. For buyers, this represents a unique opportunity to acquire a difficult-to-replicate asset for a leading position in the Diagnostic AI market. ⚠ Diligence (valuable data, access to negotiate): Highly regulated nuclear and medical industry; Sensitive aerospace and defense testing data; DOE oversight due to significant federal loan commitments · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Shinefusion possesses a proprietary dataset generated from its core industrial business in fusion technology and advanced materials testing. The data's origin in medical isotope manufacturing points to a unique collection of medical imaging assets, a highly sought-after resource for companies developing diagnostic AI. In a global AI in Diagnostics market projected to grow at a 21.5% CAGR, this dataset offers a rare opportunity to train algorithms on novel, high-value imagery, creating a distinct competitive advantage.
See dimension details ↓- Dataset Specificity90
dominant 'medical_records', sector industrial, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
real-time/streaming
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
Buyer demand is extremely high, driven by the market's rapid expansion and a forecasted 21.5% CAGR, creating an urgent need for high-quality, specialized training data. [1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License66
ownership=owned, licensing=restricted
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 data-appetite signals (1 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high, 4 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit50
⚠ review — Shinefusion (SHINE Technologies) is a nuclear technology company whose core business is producing and selling medical isotopes and providing neutron-based testing services, not a company with dormant data from another primary operation. Issues: The company's primary business is selling products (medical isotopes) and services (neutron imaging) derived directly from its core technology.; The prompt's hint 'Medical Imaging Dataset Opportunity' is misleading; the company produces isotope
- Deep Qualification80
⚠ needs review — The target is a nuclear technology firm that produces medical isotopes and provides testing services; there is no evidence it holds or sells a medical imaging dataset, making the core hypothesis unsubstantiated. [licensing restricted]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Industrial data
This is time-series data from neutron testing on critical components, a valuable asset for developing predictive maintenance AI for the aerospace, defense, and energy sectors.
Medical records / imaging
This evidence confirms a unique image dataset derived from the complex process of medical isotope manufacturing, offering a proprietary source for training diagnostic AI on novel production and quality control visuals.
IoT / sensor data
This is high-frequency time-series data from fusion reactor sensors, a critical input for companies building advanced energy management systems or R&D simulation software.
Coverage
Scanned sources
Deliverable
Premium dataset report
Shinefusion Medical Imaging — a Moderate medical imaging dataset (Image modality) in the industrial domain. Primary AI use-case: Diagnostic AI. Market signal: Global Artificial Intelligence in Diagnostics Market was valued at USD 1.5 billion in 2024, with a projected CAGR of 21.5% (2025-2034) (source: Global Market Insights Inc.). [1]. Investment score 45.0/100 (confidence 0.49). Recommended action: Data Sharing Agreement.